Yale SPORE in Lung Cancer News

This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma.

New research from Yale Cancer Center provides a new understanding of patients’ views of artificial intelligence (AI) in healthcare. While comfort level varied by clinical application, most respondents had positive views about AI’s ability to improve care. Concerns surfaced when potential for misdiagnosis, privacy breaches, reduced time with clinicians, and increased costs were discussed.

OncLive®, the nation’s leading multimedia resource for oncology professionals, is pleased to announce the winners of the 10th annual Giants of Cancer Care® awards.

Roy S. Herbst, MD, PhD, has been appointed Chair of the American Association for Cancer Research (AACR) Scientific Policy and Government Affairs Committee; the appointment became effective at the AACR Annual Meeting earlier this week in New Orleans.

A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development. The research is described online ahead of print in Clinical Cancer Research.

CASE has elected a total of 35 new members, of whom 15 are from YSM/YSPH and three others are from FAS.

Lee and colleagues found that adding an investigational AURKA inhibitor to sotorasib seemed to increase cancer cell death in sotorasib-resistant cancer cells. Adding WEE1 inhibition to AURKA inhibition also seemed to increase cancer cell death. “Our results suggest that AURKA activation may contribute to intrinsic and acquired resistance to sotorasib in KRAS-mutated lung cancer cells and that inhibition of AURKA may be a promising therapeutic approach in this setting,” said Lee.

A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC).

In this video, Roy Herbst, MD, PhD, spoke with Healio about the practice changing IMpower010 trial presented at the virtual ASCO Annual Meeting. “This has been very exciting to see that the first of what will be many adjuvant trials has, at least in part, hit its endpoint,” Herbst, associate cancer center director for translational research at Yale Cancer Center, said.